NCT06380816 - A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | Biotech Hunter

Enrollment

167

Participants

Timeline

Start Date

July 9, 2024

Primary Completion Date

November 30, 2029

Study Completion Date

November 30, 2029

Conditions

Advanced Solid TumoursSquamous Cell Carcinoma of Head and NeckCarcinoma, Non-Small-Cell LungColorectal NeoplasmsTriple Negative Breast NeoplasmsCarcinoma, Renal Cell (Clear Cell Only)Esophageal NeoplasmsStomach Neoplasms (Excluding Gastrointestinal Stromal Tumors)Uterine Cervical NeoplasmsOvarian NeoplasmsPancreatic Neoplasms

Interventions

DRUG

UCB4594

Participants will receive UCB4594 as an intravenous infusion once every 3 weeks for up to 18 cycles, with each cycle lasting 21 days (\~1 year).

Trial Locations (2)

Unknown

RECRUITING

The Christie NHS Foundation Trust, Manchester

NOT_YET_RECRUITING

University Hospital Southampton NHS Foundation Trust, Southampton